Your browser doesn't support javascript.
loading
Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics.
Akinsipe, Tosin; Mohamedelhassan, Rania; Akinpelu, Ayuba; Pondugula, Satyanarayana R; Mistriotis, Panagiotis; Avila, L Adriana; Suryawanshi, Amol.
Afiliación
  • Akinsipe T; Department of Biological Sciences, College of Science and Mathematics, Auburn University, Auburn, AL, United States.
  • Mohamedelhassan R; Department of Chemical Engineering, College of Engineering, Auburn University, Auburn, AL, United States.
  • Akinpelu A; Department of Anatomy, Physiology, and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States.
  • Pondugula SR; Department of Chemical Engineering, College of Engineering, Auburn University, Auburn, AL, United States.
  • Mistriotis P; Department of Anatomy, Physiology, and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States.
  • Avila LA; Department of Biological Sciences, College of Science and Mathematics, Auburn University, Auburn, AL, United States.
  • Suryawanshi A; Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States.
Front Immunol ; 15: 1302587, 2024.
Article en En | MEDLINE | ID: mdl-38533507
ABSTRACT
The breast cancer tumor microenvironment (TME) is dynamic, with various immune and non-immune cells interacting to regulate tumor progression and anti-tumor immunity. It is now evident that the cells within the TME significantly contribute to breast cancer progression and resistance to various conventional and newly developed anti-tumor therapies. Both immune and non-immune cells in the TME play critical roles in tumor onset, uncontrolled proliferation, metastasis, immune evasion, and resistance to anti-tumor therapies. Consequently, molecular and cellular components of breast TME have emerged as promising therapeutic targets for developing novel treatments. The breast TME primarily comprises cancer cells, stromal cells, vasculature, and infiltrating immune cells. Currently, numerous clinical trials targeting specific TME components of breast cancer are underway. However, the complexity of the TME and its impact on the evasion of anti-tumor immunity necessitate further research to develop novel and improved breast cancer therapies. The multifaceted nature of breast TME cells arises from their phenotypic and functional plasticity, which endows them with both pro and anti-tumor roles during tumor progression. In this review, we discuss current understanding and recent advances in the pro and anti-tumoral functions of TME cells and their implications for developing safe and effective therapies to control breast cancer progress.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Microambiente Tumoral / Neoplasias Límite: Humans Idioma: En Revista: Front Immunol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Microambiente Tumoral / Neoplasias Límite: Humans Idioma: En Revista: Front Immunol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza